Mild Alzheimer's, Mild Cognitive Impairment
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The purpose of this study is to evaluate the effect of LY3002813 on brain scans, evaluate the safety of LY3002813 by looking at adverse events (side effects) and to look at the effect of LY3002813 on the body. The study is for research purposes only and is not intended to treat any medical condition.
Your participation could last up to 84 weeks and include 27 visits to the study center.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must present with mild cognitive impairment (for example, minor problems with mental abilities such as memory or thinking) due to Alzheimer's disease (AD) or mild-to-moderate Alzheimer's disease (AD)
Female participant must not be of childbearing potiential (for example, has had hysterectomy or without menstruation for at least 1 year)
Participant must have up to 2 reliable study partners who are in frequent contact with the participant, will accompany the participant to the office and/or be available by telephone at designated times, will monitor administration of prescribed medications and provide a separate written informed consent to participate
Participant must not have a history of bleeding inside the brain, carotid artery occlusion, stroke or epilepsy
Participant must not have gamma globulin therapy (IVIG) within the last year
Participant must be willing and able to undergo an MRI (magnetic resonance imaging)